… cell lung cancer (NSCLC) accounts for 85% of all lung cancer … A major reason for the poor
prognosis is, that lung cancer is the … Lung cancer is still the most lethal cancer diagnosis in …

… Consequently, lung cancer has become the leading cause of cancer-related mortality … -small
cell lung cancer (NSCLC) and small cell lung cancer are two classifications of lung cancer. …

Background For patients (pts) with resected, stage IB–IIIA, ALK+ NSCLC, the recommended
treatment after surgery is platinum-based chemotherapy (CT), which is associated with …

… for advanced non-small cell lung cancer (NSCLC) that is not … the treatment paradigm of lung
cancer. Anti-programmed death 1 (anti-… longer survival and manageable safety profile, being …

Background Erlotinib, docetaxel, and pemetrexed are approved for the second-line treatment
of non-small-cell lung cancer (NSCLC), but no head-to-head data from large clinical trials …

Purpose: This phase III study compared clinical efficacy and safety of the biosimilar ABP
215 with bevacizumab reference product (RP) in patients with advanced nonsquamous non–…

… Lung cancer is the second most common cancer in the world and the main reason for cancer…
and represents approximately 15 percent of all new lung cancer cases. The SCLC has high …

… lung cancer (NSCLC) is the predominant type of lung cancer, and most clinically curable
patients are diagnosed with locally advanced disease. Although the efficacy … efficacy and safety …

… efficacy and safety of AZD6244 versus pemetrexed as second- or third-line treatment in patients
with advanced non-small cell lung cancer (… evaluated the efficacy and safety of AZD6244 …

… up-to-date evidence on the efficacy and safety of combination ICI therapy for lung cancer. …
in patients with lung cancer (population), is there any difference of efficacy and safety (outcome…